IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Lindbrook Capital LLC

Lindbrook Capital LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 303 shares of the company’s stock after acquiring an additional 55 shares during the period. Lindbrook Capital LLC’s holdings in IDEXX Laboratories were worth $168,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. International Assets Investment Management LLC lifted its position in IDEXX Laboratories by 115.7% during the third quarter. International Assets Investment Management LLC now owns 1,059 shares of the company’s stock valued at $463,000 after buying an additional 568 shares in the last quarter. Global Retirement Partners LLC lifted its position in IDEXX Laboratories by 12.8% during the third quarter. Global Retirement Partners LLC now owns 344 shares of the company’s stock valued at $149,000 after buying an additional 39 shares in the last quarter. RFG Advisory LLC lifted its position in IDEXX Laboratories by 7.2% during the third quarter. RFG Advisory LLC now owns 1,026 shares of the company’s stock valued at $449,000 after buying an additional 69 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in IDEXX Laboratories by 335.3% during the third quarter. Exchange Traded Concepts LLC now owns 1,850 shares of the company’s stock valued at $809,000 after buying an additional 1,425 shares in the last quarter. Finally, Oak Thistle LLC lifted its position in IDEXX Laboratories by 46.9% during the third quarter. Oak Thistle LLC now owns 830 shares of the company’s stock valued at $363,000 after buying an additional 265 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IDXX. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. The Goldman Sachs Group boosted their target price on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research report on Tuesday, January 30th. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, Barclays boosted their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $591.50.

IDEXX Laboratories Stock Up 3.0 %

Shares of NASDAQ:IDXX opened at $493.80 on Wednesday. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. The company has a fifty day simple moving average of $535.07 and a 200 day simple moving average of $510.61. The firm has a market cap of $41.01 billion, a PE ratio of 49.04, a price-to-earnings-growth ratio of 3.69 and a beta of 1.26. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. During the same quarter in the previous year, the firm earned $2.05 earnings per share. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now owns 79,247 shares in the company, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares in the company, valued at $16,939,557.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock worth $24,871,960 over the last 90 days. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.